Isomorphic Labs closed a $2.1 billion Series B round, reinforcing investor backing for its AI-first approach to drug discovery. Thrive Capital led the round, joined by Alphabet and Google’s GV, with additional backers including MGX, Temasek, CapitalG, and the UK’s AI fund. Isomorphic said it will use the funding to scale its drug design engine, IsoDDE, and accelerate in-house pipeline programs toward clinical development. The company’s model ecosystem is built to operationalize chemistry and target hypotheses using advanced AI tooling connected to structure and interaction prediction. The fundraising also signals continued confidence that AI-driven molecular design can translate into development programs rather than remaining limited to research prototypes. For biotech markets, the scale of the round is a strong read-through on how capital formation is concentrating around platform bets with demonstrable partnerships and early pipeline execution.